LifeMD (LFMD) Projected to Post Quarterly Earnings on Monday

LifeMD (NASDAQ:LFMD) will likely be posting its Q4 2025 results after the market closes on Monday, March 9th. Analysts expect LifeMD to post earnings of ($0.01) per share and revenue of $48.5720 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 9, 2026 at 4:30 PM ET.

LifeMD Price Performance

NASDAQ:LFMD opened at $3.00 on Friday. LifeMD has a twelve month low of $2.56 and a twelve month high of $15.84. The company has a fifty day moving average of $3.30 and a 200-day moving average of $4.62. The firm has a market capitalization of $144.42 million, a P/E ratio of -17.65 and a beta of 1.92.

Insider Buying and Selling

In other news, CMO Jessica Friedeman sold 15,000 shares of the business’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $3.61, for a total value of $54,150.00. Following the completion of the sale, the chief marketing officer owned 205,000 shares in the company, valued at approximately $740,050. The trade was a 6.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 18.40% of the company’s stock.

Hedge Funds Weigh In On LifeMD

Several institutional investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in LifeMD during the fourth quarter worth $155,000. Invesco Ltd. increased its holdings in shares of LifeMD by 18.8% in the 4th quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock valued at $83,000 after acquiring an additional 3,870 shares during the period. XTX Topco Ltd raised its position in shares of LifeMD by 9.0% in the 4th quarter. XTX Topco Ltd now owns 82,360 shares of the company’s stock worth $281,000 after acquiring an additional 6,814 shares in the last quarter. Millennium Management LLC raised its position in shares of LifeMD by 220.8% in the 4th quarter. Millennium Management LLC now owns 216,836 shares of the company’s stock worth $739,000 after acquiring an additional 149,234 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in shares of LifeMD by 74.4% during the 4th quarter. Bridgeway Capital Management LLC now owns 76,200 shares of the company’s stock worth $260,000 after purchasing an additional 32,500 shares during the last quarter. 35.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on LFMD shares. HC Wainwright decreased their price target on LifeMD from $13.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, November 19th. Zacks Research raised shares of LifeMD from a “strong sell” rating to a “hold” rating in a research note on Friday, December 19th. Wall Street Zen downgraded shares of LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Lake Street Capital lowered their target price on shares of LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Finally, B. Riley Financial dropped their price target on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.25.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.